Health-related quality of life and estimation of the minimally important difference in the Functional Assessment of Cancer Therapy-Endocrine Symptom score in postmenopausal ER+/HER2- metastatic breast cancer with low sensitivity to endocrine therapy
<h4>Background</h4> The HORSE-BC study previously demonstrated that second-line endocrine therapy (ET) for patients with acquired endocrine-resistant metastatic breast cancer (MBC) still provided a clinically meaningful benefit. Herein, we investigated the health-related quality of life (HRQOL) in t...
保存先:
| 主要な著者: | , , , , , , , , , , , , , |
|---|---|
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
Public Library of Science (PLoS)
2022-01-01
|
| シリーズ: | PLoS ONE |
| オンライン・アクセス: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9707754/?tool=EBI |
| タグ: |
タグなし, このレコードへの初めてのタグを付けませんか!
|
